000			04073nam a22004215i 4500
999			_c367952 _d367952 _x1
001			367952
003			ES-MaUEC
005			20230102121653.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			211220s2021 sz | s |||| 0|eng d
020			_a9783030793081
024	7		_a10.1007/978-3-030-79308-1 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRM275 _b2021 EB
245	1	0	_aImmunotherapy _cedited by Aung Naing, Joud Hajjar.
250			_aFourth edition 2021
264		1	_aCham _bSpringer International Publishing _c2021
300			_a1 recurso en línea (VIII, 447 páginas) _b41 ilustraciones, 32 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aarchivo de texto _bPDF
490	0		_aAdvances in Experimental Medicine and Biology _x2214-8019 _v1342
505	0		_aImmune System in Action -- 2. Resistance to Immunotherapy: Mechanisms and Means for Overcoming -- 3. Immunotherapy for Melanoma -- 4. Immunotherapy in Lung Cancer: Are the promises of long-term benefit finally met? -- 5. Landscape of Immunotherapy in Genitourinary Malignancies -- 6. Immuno-oncology for Gynecologic Malignancies -- 7. Immunotherapy for Neuro-oncology -- 8. Immunotherapy in Gastrointestinal Malignancies -- 9. An update on immune based therapies in acute myeloid leukemia: 2021 and beyond! -- 10. CAR T-cells -- 11. Skin Reactions to Immune Checkpoint Inhibitors -- 12. Immunotherapy Mediated luminal Gastrointestinal toxicities -- 13. Hepatobiliary and Pancreatic Adverse Events -- 14. Pulmonary toxicities of immunotherapy -- 15. Immune checkpoint inhibitors (ICIs) related cardiotoxicity -- 16. Renal Toxicity -- 17. Immune-Related Oral, Otologic and Ocular Adverse Events -- 18. Neurologic Toxicities of Immunotherapy -- 19. Cancer Imaging in Immunotherapy. .
520			_aThe field of immuno-oncology continues to rapidly evolve as new insights to fight and treat cancer emerge. The fourth edition of Immunotherapy provides the most current overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. While immunotherapy has revolutionized the treatment landscape of several solid malignancies, several challenges still exist. Only a subset of patients derive clinical benefits; some do not respond at all, and others respond initially, only for their disease to progress later. Because these drugs can activate a broad range of immune cells, patients suffer from a unique set of side effects known as immune-related adverse events. As more immunotherapeutic agents are used in the clinic, it is important to provide updates about current and ongoing developments in the field to further research efforts and inform treatment decisions. The fourth edition will have a new focus on strategies to overcome the challenges associated with immunotherapy. Chapters will discuss topics such as biomarkers of response, resistance mechanisms, role of imaging in predicting immune-related adverse events, and management of immune-related adverse events. Written by leading experts conducting cutting-edge research, readers will gain up-to-date knowledge on the current state and future of immunotherapy. .
988			_aSpringer_BiomedLife_2022
650		7	_2embne _9145440 _aInmunoterapia
700	1		_aNaing, Aung _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _9683000
700	1		_aHajjar, Joud _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _9683002
776	0	8	_iPrinted edition: _z9783030793074
776	0	8	_iPrinted edition: _z9783030793098
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-79308-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE _n0
998			_b03/2022 _dz _ep _zSI